The role of soluble CD40L in immunosuppression
Open Access
- 1 January 2013
- journal article
- Published by Taylor & Francis Ltd in OncoImmunology
- Vol. 2 (1), e22546
- https://doi.org/10.4161/onci.22546
Abstract
We have recently performed the first comprehensive study of the potential immunosuppressive role of soluble CD40L (sCD40L). In addition, we demonstrated that serum sCD40L can potentially be used as an indicator of response to anticancer therapy, and/or to better identify those patients who would have best chances to benefit from tumor-targeting vaccines or other therapeutic modalities.Keywords
This publication has 10 references indexed in Scilit:
- Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive roleBlood, 2012
- Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure PathwayClinical Cancer Research, 2010
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2010
- Platelet activation in patients with advanced gastric cancerNeoplasma, 2010
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerCancer Immunology, Immunotherapy, 2009
- Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune EnhancementClinical Cancer Research, 2008
- Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 2006
- Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery diseaseAmerican Heart Journal, 2006
- A RANDOMIZED, PHASE II TRIAL OF KETOCONAZOLE PLUS ALENDRONATE VERSUS KETOCONAZOLE ALONE IN PATIENTS WITH ANDROGEN INDEPENDENT PROSTATE CANCER AND BONE METASTASESJournal of Urology, 2005
- Soluble CD40 Ligand Plasma Levels in Lung CancerClinical Cancer Research, 2004